Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor clinical outcome and currently no effective targeted therapies are available. Alantolactone (ATL), a sesquiterpene lactone, has been shown to have potential anti-tumour activity against various cancer cells. However, the underlying mechanism and therapeutic effect of ATL in the TNBC are largely unknown. In the present study, we found that --
metastases, recurrence and worse mortality rates despite systemic therapy. 2, 3 So far, due to molecular characteristics of TNBC, no efficient targeted therapy is available and surgery, radiotherapy, chemotherapy are major choices of the systemic treatment. 4, 5 However, these common systemic therapies accompany with high relapse rate and significantly affect patient's quality of life. 6 For example, generally used chemotherapeutic drugs, such as taxol and doxorubicin, exhibit high dose-limiting toxicity to tumour cells as well as normal cells, which limit their clinical usage. 7, 8 Although several clinical trials targeting TNBC specific molecules have been conducted, including poly ADP-ribose polymerase (PARP) and epidermal growth factor receptor (EGFR), but no significant improvements were observed in patients with TNBC. 9 Therefore, there is an urgent need to discover more favourable and effective anti-cancer drugs that improve therapeutic effects and prognosis of patients with TNBC.
Using plants treatment of cancers has a long history and there are more than 3000 plant species have been reported. Over the past decade, ATL has been reported to inhibit cancer cell proliferation in liver cancer, 12 lung squamous cell carcinoma (SCC), 13 breast cancer, 14 cervical cancer 15 and colorectal cancer. 16 One recent study has shown that ATL inhibits MDA-MB-231 cell growth by induction of reactive oxygen species (ROS) and ROS-mediated apoptosis. 17 However, detailed anti-cancer mechanism of ATL against TNBC is unclear, especially its direct target and effect in vivo are unknown.
Thioredoxin (Trx)/thioredoxin reductase (TrxR) system has been reported to involve in oxidative stress-induced apoptosis in cancer cells. 18, 19 Increased thioredoxin levels contribute to the cancer cell growth and resistance to chemotherapy. 19 Various anti-cancer drugs have been reported to directly or indirectly inhibit TrxR to reverse malignant characteristics. 20 Thioredoxin reductase 1 (TrxR1) is a major redox regulator in mammalian cells and has been reported to be overexpressed in many cancer cells, such as cervical, hepatoma, pancreatic, gastric, lung and breast cancers. [21] [22] [23] [24] [25] [26] Therefore, TrxR1 has emerged as a promising biomarker and drugable target for cancer therapy. This raises the questions whether TrxR1 is also overexpressed in TNBC, and whether ATL targets TrxR system to generate ROS.
In this study, we have examined the therapeutic effect and the anti-cancer mechanism of ATL on TNBC cells both in culture and in xenografts. Our study showed that ATL suppresses TNBC cell viability through inducing apoptosis and causing cell cycle arrest by ROSdependent endoplasmic reticulum (ER) stress pathway both in vitro and in vivo. In addition, TrxR1 expression and activity were significantly increased in TNBC specimens compared to the normal breast specimens. We also found that ATL can effectively inhibit TrxR1 in vitro and in vivo. The present study provides strong evidences that ATL can be a clinical candidate drug for the treatment of TNBC.
| MATERIALS AND METHODS
See Supplementary file.
| RESULTS

| ATL effectively induces cell death in human TNBC cells
Previous studies have reported that ATL can suppress cell viability in several tumour types. Recent evidence suggests that ATL ( Figure 1A) can inhibit human breast cancer cell line, MDA-MB-231 cell growth.
To better understand the effect of ATL on TNBC cell viability, we Treatment of TNBC cells with ATL decreased Bcl-2 ( Figure 1E ) while increased the levels of Bax. As caspase-3 is a crucial component of the apoptotic machinery, and the cleavage of caspase-3 is a central event in the process of apoptosis, we further examined the expression of cleaved caspase-3. As shown in Figure 1E , the cleaved forms of caspase-3 were increased in TNBC cells exposed to ATL. These data suggest that ATL could induce apoptosis of TNBC cells. Figure 2C ).
Furthermore, colony formation assay also showed that ATL significantly prevented colony formation of TNBC cells at 5 and 10 μmol/L levels ( Figure 2D ).
| ATL increases ROS levels in human TNBC cells
Reactive oxygen species accumulation has been reported to induce apoptosis in several cancer cells. 27, 28 To examine whether apoptosis We next wanted to check whether the negative growth signals from ATL can be attenuated by reduction of ROS levels. Pre-treatment of cells with NAC (1 mmol/L) was able to attenuate ATL-induced apoptosis ( Figure 3F ; Figure S1A ,B) and cell cycle arrest 
| ROS-dependent ER stress pathway contributes to ATL lethality in TNBC cells
Increased ROS levels and imbalance of the intracellular redox status increase unfolded proteins in the ER and induce ER stress response. 29 Endoplasmic reticulum stress or unfolded protein On the other hand, ATF6α-dependent UPR has shown cytoprotective functions leading to oncogenic roles in tumourigenesis. 32, 33 We found that ATL treatment markedly increased XBP1S expres- 
| TRXR1 is up-regulated in clinical TNBC cancer tissues and inactivated by ATL
Thioredoxin reductase 1 overexpression has been reported in several malignancies. Overexpression of TrxR1 was associated with aggressive tumour growth and poor survival. In addition, it has been reported that TrxR system contributes to tumour cell resistance to oxidative stress. 18 We firstly examined TrxR1 mRNA expression in TNBC. GSE59590 dataset showed that sues. Further, we tested the TrxR1 enzyme activity by using the 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) assay. As shown in Figure 5E and F, the activities of TrxR1 in tumours were significantly up-regulated compared to the corresponding normal breast specimens. All together, these findings indicate that TrxR1 might play pivotal functions in TNBC carcinogenesis.
We next want to know whether TrxR1 is a target of ATL in TNBC cells. A recent study showed that ATL inhibits the recombinant TrxR1 in HeLa cells. 34 To investigate the structural mechanism of ATL binding to the TrxR1 protein, we performed a molecular simulation of ATL-TrxR1 complex using AutoDock. Our result showed that ATL not only can insert into the C-terminal active site of TrxR1 but also form a strong covalent bond (Figure 5G ). It has been reported that the redox motif containing
Cys-497, Sec-498 plays a vital role in enzyme inactivation, thus competitive inhibition to these residues could significantly desensitize the enzyme. 35, 36 During the docking process, the alkenyl in ATL was detected as Michael acceptor to form a hard covalent bond with Cys-497 while the cyclohexane part inserted into the hydrophobic pocket. Thus occupying the redox active centre may block the nature enzymatic recognition. This docking study suggests that TrxR1 is the potential target of ATL and blocking the critical residues in redox centre could inhibit its enzyme activity.
We further tested the direct inhibitory effects of ATL on TrxR1 enzyme activity by using DTNB assay. When lysates prepared from MDA-MB-231 cells were incubated with various concentrations of ATL for 2 h, the DTNB reducing activity of TrxR1 decreased in a dose-dependent manner ( Figure 5H ). We confirmed these results by measuring TrxR1 enzyme activity in pre- F I G U R E 4 ROS-dependent endoplasmic reticulum (ER) stress pathway is involved in alantolactone (ATL)-induced triple-negative breast cancer (TNBC) cell's growth inhibition. A, MDA-MB-231 cells were exposed to 30 μmol/L ATL for the indicated times. Protein levels of ATF4, phosphorylated eIF2α and CHOP were determined by western blot. GAPDH served controls. B, Western blot analysis of ER-stress pathway associated proteins in MDA-MB-231 cells exposed to various doses of ATL for 9 h. C, MDA-MB-231 cells were pre-treated with 1 mmol/L NAC prior to 30 μmol/L ATL exposure. Endoplasmic reticulum-stress pathway associated proteins levels were detected by western blot. D, Electron microscopy images of MDA-MB-231 cells exposed to ATL (10 000× and 20 000× shown] . Cells were exposed to 30 μmol/L ATL for 9 h, with or without pre-treatment with 1 mmol/L NAC for 1 h. E, MDA-MB-231 cells were transfected with ATF4 siRNA or control siRNA, ATF4 expression in MDA-MB-231 cells was determined by Western blotting after treating with ATL (30 μmol/L) for 9 h. F, Effect of ATF4 knockdown on ATL-induced apoptosis was determined by annexin V/propidium iodide (PI) staining and flow cytometry. MDA-MB-231 cells were transfected with ATF4 siRNA or control siRNA for 24 h and then exposed to ATL (30 μmol/L) for 24 h. G, Quantification of annexin V/PI staining presented as the percentage of apoptotic cells following treatment (*P < 0.05, **P < 0.01 and***P < 0.001 compared to DMSO control) （n = 2） observed in various malignancies including breast cancer. [21] [22] [23] [24] [25] [26] 38 In addition, it has been demonstrated that TrxR1 plays an important function in tumour growth, progression, metastasis and chemotherapy resistance. [39] [40] [41] Our patient sample analyses, in agreement with publicly available GSE59590 dataset validated that TrxR1 expression and its activity were significantly increased in TNBC tissue samples compared to the NAT and other types of breast cancer samples. In addition, our study first time showed that ATL can suppress TrxR1 activity in the TNBC cell line MDA-MB-231 cells and its xenograft models. ATL inhibits TrxR1 activity, suppresses TNBC cell growth in xenografts by increasing accumulation of ROS in tissues, and leading to ROS-dependent ER stress. Taken together, our study indicates that TrxR1 may serve as a promising biomarker and target molecule for TNBC therapy.
In conclusion, our study showed the potential usefulness and novel molecular mechanism of ATL in the treatment of TNBC. We found that ATL treatment resulted in significant ROS accumulation by inhibition of TrxR1 activity. ROS accumulation caused the activation of the ER stress-mediated apoptotic pathway both in vitro and in vivo. Considering no efficient targeted therapy in TNBC and ATL effectively inhibits tumour growth of TNBC in vivo without obvious side effects, ATL might be a potential anti-tumor drug in TNBC.
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Schematic illustration of the proposed anti-cancer mechanism of alantolactone (ATL) in triple-negative breast cancer (TNBC). We show first time that ATL significantly inhibits thioredoxin reductase 1 (TrxR1) activity leading to increased ROS levels in the TNBC cells and its xenograft models. ROS accumulation causes the activation of the endoplasmic reticulum (ER) stress pathway/unfolded protein response and contributes the ROS-induced cell death by activating caspases in TNBC cell lines and in a mouse pre-clinical model . Tumour volumes were calculated as described in the methods section. (*P < 0.05). C, Body weight of the mice in four groups (n = 6). D, Hematoxylin and eosin staining of heart, liver and kidney specimens (magnification 200×). E, Levels of malondialdehyde (MDA) in tumour tissue lysates (*P < 0.05, **P < 0.01 compared to vehicle treated group) (n = 3). F, Fluorescence images of tumour specimens stained with DHE (red) and DCFH-DA (green) and tissue sections were counterstained with 4′,6-diamidino-2-phenylindole (blue). Increased fluorescence intensity is indicative of increased ROS levels (magnification 200×). G, Western blot analysis of ATF4, CHOP and Cleaved-caspase3 levels in tumour tissues. GAPDH was used as loading control. H, Representative immunohistochemical staining images of cell proliferation marker (Ki-67) and apoptosis marker (Cleaved caspase-3) in tumour tissues. I, Activity of TrxR1 in tumour tissue lysates as determined by end-point insulin reduction assay. (*P < 0.05, **P < 0.01, compared to vehicle treated mice) (n = 3)
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